



## The Effect of Head-up Tilt upon Markers of Heart Rate Variability in Patients with Atrial Fibrillation

Journal:	<i>Annals of Noninvasive Electrocardiology</i>
Manuscript ID	ANEC-17-3373.R1
Manuscript Type:	Original Article
Date Submitted by the Author:	n/a
Complete List of Authors:	<p>Patel, Hitesh; Baker IDI Heart and Diabetes Institute; Royal Brompton and Harefield NHS Foundation Trust, NIHR Cardiovascular Biomedical Research Unit; National Heart and Lung Institute, Imperial College          Hayward, Carl; Royal Brompton and Harefield NHS Foundation Trust, NIHR Cardiovascular Biomedical Research Unit; National Heart and Lung Institute, Imperial College          Wardle, Andrew; Imperial College Healthcare NHS Trust          Middleton, Lee; London North West Healthcare NHS Trust          Lyon, Alexander; Royal Brompton and Harefield NHS Foundation Trust, NIHR Cardiovascular Biomedical Research Unit; National Heart and Lung Institute, Imperial College          Di Mario, Carlo; Royal Brompton and Harefield NHS Foundation Trust, NIHR Cardiovascular Biomedical Research Unit; National Heart and Lung Institute, Imperial College; Azienda Ospedaliero Universitaria Careggi, Structural Interventional Cardiology          Salukhe, Tushar; Royal Brompton and Harefield NHS Foundation Trust, NIHR Cardiovascular Biomedical Research Unit; National Heart and Lung Institute, Imperial College          Sutton, Richard; National Heart and Lung Institute, Imperial College          Rosen, Stuart; Royal Brompton and Harefield NHS Foundation Trust, NIHR Cardiovascular Biomedical Research Unit; National Heart and Lung Institute, Imperial College; London North West Healthcare NHS Trust</p>
Keywords:	Atrial fibrillation/atrial arrhythmias < Basic, Non-invasive techniques - heart rate variability < Clinical, Non-invasive techniques - head-up tilt testing < Clinical

1  
2  
3 1 **The Effect of Head-up Tilt upon Markers of Heart Rate Variability in Patients with**  
4  
5 2 **Atrial Fibrillation**

6  
7 3  
8  
9 4 **Running head: HRV in AF, is it plausible?**  
10  
11 5

12  
13  
14 6 **Hitesh C Patel,<sup>1,4#</sup> Carl Hayward,<sup>1,4#</sup> Andrew J Wardle,<sup>2</sup> Lee Middleton,<sup>3</sup> Alexander R**  
15  
16 7 **Lyon,<sup>1,4</sup> Carlo Di Mario,<sup>1,4</sup> Tushar V Salukhe,<sup>1,4</sup> Richard Sutton<sup>4</sup> and Stuart D Rosen.<sup>3,4</sup>**  
17  
18 8

19  
20  
21 9 <sup>1</sup>NIHR Cardiovascular Biomedical Research Unit, Royal Brompton Hospital, Sydney Street,  
22  
23 10 London, UK

24  
25 11 <sup>2</sup>Hammersmith Hospital, Du Cane Road, London, UK

26  
27 12 <sup>3</sup>Department of Cardiology, Ealing Hospital, Uxbridge Road, Southall, UK

28  
29 13 <sup>4</sup>National Heart and Lung Institute, Imperial College, London, UK

30  
31 14 # Denotes authors contributed equally  
32  
33

34 15

35  
36 16 **Corresponding Author:**

37  
38 17 Dr Hitesh Patel

39  
40 18 Cardiology Research Fellow

41  
42 19 NIHR Cardiovascular Biomedical Research Unit

43  
44 20 Royal Brompton and Harefield NHS Foundation Trust,

45  
46 21 Sydney Street

47  
48 22 London SW3 6NP

49  
50 23 Tel: +44 207 352 8121 Ext 2920

51  
52 24 Fax: +44 207 351 8146

53  
54 25 Email: [dochiteshpatel@hotmail.com](mailto:dochiteshpatel@hotmail.com)  
55  
56  
57  
58  
59  
60

1  
2  
3 26  
45 27 **Abstract**

6  
7 28 **Background:** Heart rate variability (HRV) analysis is uncommonly undertaken in patients  
8  
9 29 with atrial fibrillation (AF) due to an assumption that ventricular response is random. We  
10  
11 30 sought to determine the effects of head up tilt (HUT), a stimulus known to elicit an  
12  
13 31 autonomic response, on HRV in patients with AF; we contrasted the findings with those of  
14  
15 32 patients in sinus rhythm (SR).

16  
17 33 **Methods:** Consecutive, clinically indicated tilt tests were examined for 207 patients: 176 in  
18  
19 34 SR, 31 in AF. Patients in AF were compared to an age-matched SR cohort (n=69). Five  
20  
21 35 minute windows immediately before and after tilting were analysed using time-domain,  
22  
23 36 frequency-domain and non-linear HRV parameters. Continuous, non-invasive assessment of  
24  
25 37 blood pressure, heart rate and stroke volume were available in the majority of patients.  
26  
27

28  
29 38 **Results:** There were significant differences at baseline in all HRV parameters between AF  
30  
31 39 and age matched SR. HUT produced significant haemodynamic changes, regardless of  
32  
33 40 cardiac rhythm. Co-incident with these haemodynamic changes, patients in AF had a  
34  
35 41 significant increase in median [quartile 1, 2] DFA- $\alpha 2$  (+0.14 [-0.03, 0.32],  $p < 0.005$ ) and a  
36  
37 42 decrease in sample entropy (-0.17 [-0.50, -0.01],  $p < 0.005$ ).

38  
39 43 **Conclusion:** In the SR cohort, increasing age was associated with fewer HRV changes on  
40  
41 44 tilting. Patients with AF had blunted HRV responses to tilting, mirroring those seen in an age  
42  
43 45 matched SR group. It is feasible to measure HRV in patients with AF and the changes  
44  
45 46 observed on HUT are comparable to those seen in patients in sinus rhythm.  
46  
47

48  
49 47 **Keywords:** Atrial Fibrillation; Heart Rate Variability; ECG Signal Processing; Head-up Tilt  
50  
51

52 48  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 49 Heart rate variability (HRV) is a surrogate marker for the function of the autonomic nervous  
4  
5 50 system (ANS) and the technique is widely available (Task Force of the European Society of  
6  
7 51 Cardiology and the North American Society of Pacing and Electrophysiology, 1996). There  
8  
9  
10 52 are a variety of methods for the derivation of HRV, through the application of different  
11  
12 53 mathematical functions to consecutive RR-intervals. These mathematical functions fall  
13  
14 54 broadly into three groups: time domain, frequency domain and non-linear analysis (Task  
15  
16 55 Force of the European Society of Cardiology and the North American Society of Pacing and  
17  
18 56 Electrophysiology, 1996).

19  
20  
21  
22  
23 58 A relationship between reduced HRV and prognosis has been shown in health (Hillebrand et  
24  
25 59 al., 2013) and in numerous conditions, including after myocardial infarction and in patients  
26  
27 60 with heart failure (Bilchick et al., 2002).

28  
29  
30  
31  
32 62 HRV techniques are generally not applied to patients in atrial fibrillation (AF) (Task Force of  
33  
34 63 the European Society of Cardiology and the North American Society of Pacing and  
35  
36 64 Electrophysiology, 1996). This is an important limitation, as AF is not only very prevalent  
37  
38 65 but it is present in 30-50% of the heart failure population, a condition in which HRV has been  
39  
40 66 shown to be useful in predicting outcomes (Bilchick, et al., 2002). Recently, bridging this gap  
41  
42 67 in knowledge has become even more pertinent due to the introduction of ablative  
43  
44 68 interventions or device implantation (e.g. renal denervation, baroreceptor stimulators, vagal  
45  
46 69 nerve stimulators, spinal cord stimulators) which modulate the ANS as a potential treatment  
47  
48 70 strategy in heart failure and other diseases (Ardell et al., 2014; Patel et al., 2013).

49  
50  
51  
52  
53  
54 72 The argument against the use of HRV techniques in patients with AF is based upon the  
55  
56 73 assertion that the RR intervals in AF are truly less dependent on physiological mechanisms  
57  
58  
59  
60

1  
2  
3 74 measureable with HRV. Though in clinical examination AF is characterised crudely by an  
4  
5 75 irregularly irregular pulse, generally considered random, there is a growing body of evidence  
6  
7 76 that supports a different view (Carrara et al., 2015; Cygankiewicz et al., 2015; Hayano,  
8  
9 77 Sakata, Okada, Mukai, & Fujinami, 1998; Hayano et al., 1997; Rawles & Rowland, 1986).  
10  
11 78 Rawles and Rowland demonstrated in 74 patients in AF, using an auto-correlation technique,  
12  
13 79 that at rest approximately a third of patients had a non-random ventricular rhythm (Rawles &  
14  
15 80 Rowland, 1986). While the effect of the ANS on the sinus node is a major determinant of  
16  
17 81 HRV in sinus rhythm (SR), the ANS is equally important in AF, through its effects on the  
18  
19 82 refractory period and conductivity of the AV node, the frequency and irregularity of atrial  
20  
21 83 impulses and the degree of concealed conduction (Bollmann et al., 2006; Hayano, et al.,  
22  
23 84 1998; Lim et al., 2011).  
24  
25  
26  
27  
28

29  
30 86 The purpose of this study was to determine the validity of measuring HRV in patients with  
31  
32 87 AF. To achieve this we used head-up tilt testing (HUT) as an intervention that predictably  
33  
34 88 activates the sympathetic nervous system (SNS) and leads to withdrawal of the  
35  
36 89 parasympathetic nervous system (PNS) (Mehlsen, Kaijer, & Mehlsen, 2008). We contrasted  
37  
38 90 the effects of HUT on HRV in a cohort of individuals with AF and a group in SR.  
39  
40  
41

42  
43 92 The ageing process is an important consideration in studies of autonomic physiology  
44  
45 93 (Petersen, Williams, Gordon, Chamberlain-Webber, & Sutton, 2000). Not only is increasing  
46  
47 94 age a risk factor for AF but it has also been shown to reduce HRV in cross sectional studies  
48  
49 95 (Laitinen, Niskanen, Geelen, Lansimies, & Hartikainen, 2004; Sosnowski, Macfarlane, &  
50  
51 96 Tendra, 2011; Task Force of the European Society of Cardiology and the North American  
52  
53 97 Society of Pacing and Electrophysiology, 1996). It is vital that we match for age and interpret  
54  
55 98 our findings in the context of a more elderly population. To aid this interpretation we carried  
56  
57  
58  
59  
60

1  
2  
3 99 out additional analyses on a cohort in SR to establish the effect of aging on HRV responses to  
4  
5 100 tilt in our patients.

6  
7 101

8  
9 102 **Methods**

10 103 *Study Patients*

11  
12  
13  
14 104 We obtained data retrospectively on consecutive patients with permanent AF who underwent  
15  
16 105 clinically indicated tilt testing at two hospitals (over a cumulative 9 years). All patients in SR  
17  
18 106 from one of the hospitals also had their data analysed to provide the control population.

19  
20  
21 107 Patients were excluded from this analysis if they experienced syncope or pre-syncope in the  
22  
23 108 tilt phase or had a paced rhythm. Data was available for 176 patients in SR and 31 in AF.

24  
25 109 National Health Service (UK) management permission for use of anonymised patient data for  
26  
27 110 ethical research was obtained.

28  
29  
30 111

31  
32 112 *Tilt-test protocol*

33  
34 113 The tilt table examination was performed in a dedicated room. Patients were fasted for two  
35  
36 114 hours prior to the HUT and did not have medications stopped. A motorised bed with footplate  
37  
38 115 support was used to achieve tilt angles of 60-80°. Each patient had a 10 minute supine  
39  
40 116 baseline period after which they were subjected to 20 minutes of tilt.

41  
42  
43 117

44  
45 118 *Data acquisition and pre-processing*

46  
47 119 Continuous, non-invasive, high resolution, beat-to-beat heart rate (1000 Hz sampling  
48  
49 120 frequency) and blood pressure monitoring (500 Hz sampling frequency) was performed at  
50  
51 121 both sites using either the Task Force® Monitor (CNS SystemsMedizintechnik AG, Graz,  
52  
53 122 Austria) or Nexfin® (BMEYE B.V, Amsterdam, Holland). The Task Force® Monitor also  
54  
55 123 estimates cardiac output and total peripheral resistance using impedance cardiography.  
56  
57  
58  
59  
60

1  
2  
3 124  
4

5 125 Time series for heart rate (beat to beat NN intervals) were extracted and automatically filtered  
6  
7 126 to exclude artefacts and ectopics using a validated and freely available programme Kubios  
8  
9 127 HRV (<http://kubios.uef.fi>).  
10

11 128  
12

13  
14 129 *Heart Rate Variability*  
15

16 130 We standardized our analysis windows to five minutes to minimize bias as it is known that  
17  
18 131 the total variance of HRV increases in proportion to the length of recording, in line with  
19  
20 132 international recommendations (Task Force of the European Society of Cardiology and the  
21  
22 133 North American Society of Pacing and Electrophysiology, 1996). Windows immediately  
23  
24 134 before and during the first five minutes of HUT were analysed. Time domain, frequency  
25  
26 135 domain and non-linear methods for determining HRV were applied to the data (Task Force of  
27  
28 136 the European Society of Cardiology and the North American Society of Pacing and  
29  
30 137 Electrophysiology, 1996).  
31  
32

33 138  
34  
35

36 139 Time domain analysis involves application of simple statistical techniques straight to the  
37  
38 140 successive RR intervals. We elected to study only SDRR (standard deviation of successive  
39  
40 141 RR intervals) and RMSSD (root of the mean squared differences of successive RR intervals)  
41  
42 142 (Tarvainen, Niskanen, Lipponen, Ranta-Aho, & Karjalainen, 2014) as both of these  
43  
44 143 parameters can be used in 5 minute recordings of RR intervals and the other time domain  
45  
46 144 parameters are either derived from them or are highly correlated to them (Task Force of the  
47  
48 145 European Society of Cardiology and the North American Society of Pacing and  
49  
50 146 Electrophysiology, 1996).  
51

52 147  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 148 Frequency domain analysis required the RR interval time series to be converted to an  
4  
5 149 equidistantly sampled series and this was performed using the cubic spline interpolation  
6  
7 150 method (Tarvainen, et al., 2014). The power spectral density was estimated using parametric  
8  
9 151 autoregressive modelling (order number 16 without factorisation) and absolute power in the  
10  
11 152 low frequency (LF: 0.04-0.15 Hz) and high frequency (HF: 0.15-0.4 Hz) bands calculated  
12  
13  
14 153 (Tarvainen, et al., 2014). These powers can be normalised to minimise the effects of changes  
15  
16 154 in total power on this parameters, e.g. normalised LF (LFnu) is calculated as:  $LF/(Total$   
17  
18 155  $power - very\ low\ frequency\ power)$ . Due to the algebraic relationship with normalised  
19  
20 156 frequency domain parameters, whereby the sum of LFnu and HFnu is always equal to one,  
21  
22 157 we have opted to present only unique data and arbitrarily chose to present LFnu.  
23  
24  
25 158  
26  
27 159 Finally we also applied the following non-linear methods of HRV analysis: Poincaré plots,  
28  
29 160 detrended fluctuation analysis and entropy. Poincaré plots are a graphical representation of  
30  
31 161 the correlation between successive RR intervals. It can be assessed qualitatively by looking at  
32  
33 162 the shape of the plot and quantitatively by fitting an ellipse to the plot and calculating the  
34  
35 163 standard deviation of the points perpendicular to the line of identity (SD1) and along the line  
36  
37 164 of identity (SD2) (Tarvainen, et al., 2014).  
38  
39  
40 165  
41  
42 166 Detrended fluctuation analysis measures correlation with the signal for different time scales.  
43  
44 167 A series of RR intervals are integrated and are divided into a series of regular intervals. For  
45  
46 168 each interval the fluctuation of the data from a straight line of linear interpolation is  
47  
48 169 calculated. DFA- $\alpha_1$  corresponds to short-term fluctuations within an interval range of 4-16  
49  
50 170 whereas DFA- $\alpha_2$  characterises longer-term fluctuations within the interval range of 16-64  
51  
52 171 (Tarvainen, et al., 2014).  
53  
54  
55 172  
56  
57  
58  
59  
60



1  
2  
3 173 Sample entropy, which refers to the degree of irregularity or randomness with a series and are  
4  
5 174 estimates for the negative natural logarithm of the condition probability that a length of data  
6  
7 175 having repeated itself within a tolerance  $r$  for  $m$  points, will also repeat itself for  $m+1$  points.  
8  
9  
10 176 We used the default value of  $m=2$  and  $r=0.2$ SDRR (Tarvainen, et al., 2014).

11  
12 177

### 13 178 *Statistics*

14  
15  
16 179 Some of the HRV parameters were not normally distributed and so we adopted non-  
17  
18 180 parametric statistical analysis throughout for consistency. Continuous variables are  
19  
20 181 summarised as median (quartile 1, quartile 3) and compared using the Mann-Whitney U test  
21  
22 182 (independent samples), the Kruskal-Wallis test (more than two independent samples) and the  
23  
24 183 Wilcoxon signed rank test (dependent samples, i.e. comparing parameters before and after  
25  
26 184 HUT in the same cohort). Categorical variables are presented as counts or proportions (%)  
27  
28 185 and analysed using Fisher's exact test. Strength of correlation between variables are  
29  
30 186 presented using the Pearson's product-moment correlation ( $r$ ). A  $P \leq 0.05$  was considered  
31  
32 187 statistically significant for analysis of baseline clinical features and haemodynamics of  
33  
34 188 patients. This level of significance was made more stringent to  $P \leq 0.005$  when analysing the  
35  
36 189 HRV parameters using the Bonferroni method to correct for multiple testing. A concern with  
37  
38 190 the Bonferroni method is that it can elevate the type II error rate (accepting the null  
39  
40 191 hypothesis when the alternative is correct) and for that reason we have also provided  
41  
42 192 complete P values or at least made a summative distinction between a parameter that changed  
43  
44 193 at  $P < 0.05$  and one at  $P < 0.005$ . All analyses were performed using SPSS (Version 22, IBM).

45  
46  
47  
48  
49 194

### 50 195 **Results**

51  
52 196 Data were available in total for 176 patients in SR and 31 patients in AF. Of these, all SR  
53  
54 197 patients and 19 AF patients were from the same institution and had a full data set including  
55  
56  
57  
58  
59  
60

1  
2  
3 198 non-invasive beat to beat heart rate, blood pressure, stroke volume and peripheral resistance.

4  
5 199 Data for the remaining 12 patients in AF was obtained from another institution for whom

6  
7 200 non-invasive stroke volume or peripheral resistance measurements were not available.

8  
9 201 Correlations between HRV variables at rest

10  
11 202

12  
13 203 *The effect of HUT in AF and SR*

14  
15 204 The demographics of the 31 patients in AF and 69 age-matched patients in SR are

16  
17 205 summarised in Table 1. Patients with AF were significantly more likely to have hypertension

18  
19 206 and be on more medications (angiotensin converting enzyme inhibitor, angiotensin receptor

20  
21 207 blocker, beta-blocker, calcium channel blocker and digoxin). Only 7 (22.6%) patients with

22  
23 208 AF were not on any of the six classes of medication detailed in Table 1, compared with 54

24  
25 209 (78.3%) in the SR cohort.

26  
27 210

28  
29 211 HUT causes a decrease in stroke volume, which is coupled with an increase in blood pressure

30  
31 212 (diastolic), heart rate and total peripheral resistance (Table 2). The magnitude and direction of

32  
33 213 change, though similar for both cohorts, were statistically more convincing in patients with

34  
35 214 SR.

36  
37 215

38  
39 216 All HRV parameters at rest were significantly different between the AF and SR cohorts. On

40  
41 217 HUT only 2 parameters (DFA- $\alpha$ 2 and sample entropy) changed significantly ( $P < 0.005$ ) in

42  
43 218 both groups (Table 2). SDRR, LFnu and SD2 increased in patients in SR on HUT, whereas

44  
45 219 HF decreased in patients with AF at the uncorrected significance level of  $p < 0.05$ . There was

46  
47 220 no overall difference in the direction of change between either group.

48  
49 221

50  
51 222 *The effect of aging on cardiovascular autonomic reflexes*

52  
53 223

1  
2  
3 223 The cohort of 176 patients in SR was divided into tertiles of age (with median ages 22, 47  
4 and 73 years). Their demographic data are detailed in Table 3 and suggests that the three  
5  
6 224  
7 groups were balanced apart from there being proportionally more females in the youngest  
8  
9 225  
10 226 cohort. In particular there were no differences with respect to prescribed medications.

11 227

12  
13  
14 228 There were significant differences at rest between the 3 tertiles of age with respect to  
15  
16 229 haemodynamic function and HRV (Table 4). Stroke volume index decreased with age,  
17  
18 230 whereas resting heart rate did not change. With advancing age all of the HRV parameters  
19  
20 231 except for DFA- $\alpha$ 1 and DFA- $\alpha$ 2 were significantly attenuated (Table 4). Throughout the  
21  
22 232 tertiles of age, upon HUT, blood pressure, heart rate and total peripheral resistance index  
23  
24 233 increased whilst stroke volume index decreased. However, the augmentation in heart rate was  
25  
26 234 attenuated as was the decline in stroke volume index with increasing age. Furthermore, the  
27  
28 235 HRV response to HUT became blunted with age, with 11/12 HRV parameters changing at a  
29  
30 236 significance level of  $p < 0.005$  in the youngest tertile, 9/12 in the middle cohort and only 2/12  
31  
32 237 in the oldest tertile.

33  
34  
35  
36 238

37  
38 239 Correlations between each of the HRV parameters in the SR (N=176) and AF (N=31) cohorts  
39  
40 240 are shown in Table 5. There were strong correlations some of the non-linear parameters  
41  
42 241 (SD1, SD2 and DFA- $\alpha$ 1) and linear parameters.

43  
44  
45 242

## 46 47 243 **Discussion**

48  
49 244 The main findings of this study are: 1) For patients in sinus rhythm, HRV at rest and in  
50  
51 245 response to HUT attenuates with age; 2) Patients in AF demonstrate similar changes in HRV  
52  
53 246 on HUT to an age-matched cohort in SR; 3) The non-linear measures of HRV appear more  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 247 discriminatory in both AF compared with the conventional linear methods (time and  
4  
5 248 frequency domain).

6  
7 249

8  
9  
10 250 **The effect of age on cardiovascular responses to HUT in SR patients**

11 251 *Haemodynamics*

12  
13  
14 252 The process of shifting from a supine to an upright position results in an immediate reduction  
15  
16 253 in venous return and up to a 20% reduction in stroke volume. In response, there is an  
17  
18 254 activation of various homeostatic pathways, one of which is the ANS, which functions to  
19  
20 255 maintain cerebral blood flow and prevent syncope (Mourot et al., 2007). In our cohort, we  
21  
22 256 demonstrated that our HUT protocol was effective in inducing an adequate haemodynamic  
23  
24 257 stress. We observed a reduction in stroke volume index, which was associated with an  
25  
26 258 increase in blood pressure, heart rate and total peripheral resistance index.  
27  
28

29  
30 259

31  
32 260 In the supine position, the oldest tertile had the lowest stroke volume and compared with the  
33  
34 261 youngest tertile had higher blood pressures and vascular resistance. Upon HUT, the increase  
35  
36 262 in heart rate was less pronounced in the older cohort as was the decrease in stroke index.  
37  
38 263 Cumulatively, these responses seek to maintain cardiac output (heart rate x stroke volume  
39  
40 264 indexed for body surface area). Laitinen and colleagues described the effect of ageing upon  
41  
42 265 response to HUT in 63 individuals and found results different from ours (Laitinen, et al.,  
43  
44 266 2004). Similar to our data they showed that elderly subjects had smaller increases in heart  
45  
46 267 rate, however, in contrast to our findings they showed that this cohort also had a larger  
47  
48 268 decrease in stroke volume and larger increase in total peripheral resistance upon HUT. The  
49  
50 269 most likely explanation is that the two studies have examined different populations. Laitinen  
51  
52 270 and colleagues studied a healthy population who were not on any medication compared with  
53  
54 271 our cohort who all had previously experienced syncope and at least a fifth had other  
55  
56  
57  
58  
59  
60

1  
2  
3 272 significant co-morbidities. Medications are known to influence cardiovascular responses but  
4  
5 273 in our SR cohort there were no significant differences between the tertiles of age with respect  
6  
7 274 to blood pressure lowering medications. Furthermore, there were differences between our  
8  
9 275 studies with respect to when data were collected. In Laitinen's study all patients were rested  
10  
11 276 supine for 3 hours before a 5 minute baseline recording of heart rate was obtained (our  
12  
13 277 protocol mandated a 10 minute rest period ) and were sampled at minutes 5-10 after HUT  
14  
15  
16 278 (our protocol mandated minutes 0-5).  
17  
18  
19 279

### 20 280 *Heart rate variability*

21  
22 281 Ageing affects HRV both at rest and under dynamic testing using HUT. Consistent with the  
23  
24 282 wider literature our data confirm that HRV reduces with age, both at rest and in response to  
25  
26 283 HUT (Sosnowski, et al., 2011). At rest, we did not find a change in either DFA- $\alpha$ 1 or DFA-  
27  
28 284  $\alpha$ 2 with age. Others have reported similar results whilst some groups have shown a decrease  
29  
30 285 in DFA- $\alpha$ 1 and an increase in DFA- $\alpha$ 2 with advancing age in health volunteers (Shiogai,  
31  
32 286 Stefanovska, & McClintock, 2010; Voss, Schroeder, Heitmann, Peters, & Perz, 2015). The  
33  
34 287 likely contributors to this discrepancy are: 1) our study population were not healthy  
35  
36 288 volunteers; 2) approximately a fifth of our population in SR were on cardiovascular  
37  
38 289 medications (V. D. Corino et al., 2013); and 3) our study numbers were modest and hence our  
39  
40 290 investigation may be underpowered.  
41  
42  
43  
44  
45 291

46  
47 292 In the youngest tertile (0-30 years), seven of the nine HRV parameters changed significantly  
48  
49 293 on HUT. Only SDRR and its correlate SD2 did not change.(Hoshi, Pastre, Vanderlei, &  
50  
51 294 Godoy, 2013) In the 30-60 years of age cohort, RMSSD also failed to change significantly  
52  
53 295 with HUT. Finally in the 60 years and older cohort, only two HRV parameters changed (at  
54  
55 296  $p < 0.005$ ), DFA- $\alpha$ 2 and sample entropy, both of them non-linear parameters. Studies  
56  
57  
58  
59  
60

1  
2  
3 297 examining the effect of HUT upon HRV, using time and frequency domain, mirror our  
4  
5 298 findings and have concluded that the response to HUT in younger individuals reflects  
6  
7 299 parasympathetic withdrawal at the cardiac level, which diminishes with ageing and is  
8  
9 300 associated with a concomitant increase in sympathetic tone to the periphery (Laitinen, et al.,  
10  
11 301 2004).

302

### 303 **Comparison of responses in patients with AF and SR**

304 Frequency domain analyses of HRV in AF have failed to detect changes in response to  
305 manoeuvres known to affect HRV in SR and our data lends further support to this assertion  
306 (Hayano, et al., 1997; Leung et al., 2005). DFA- $\alpha$ 2 and sample entropy are the only two HRV  
307 parameters that changed significantly ( $p < 0.005$ ) in patients in AF and/or age-matched SR  
308 upon HUT. Though the direction of change was identical between the two groups, the  
309 magnitude of difference is likely to be different (though we are statistically underpowered to  
310 demonstrate the latter). Furthermore there were three other HRV parameters that changed in  
311 patients with SR but did not in AF, when the type 1 error rate was reduced to 0.05: SDRR,  
312 SD2, LFn<sub>u</sub> (the former two have previously been shown to be well positively  
313 correlated). (Hoshi, et al., 2013) It is not unexpected to see differences in HRV effects, since  
314 our two populations are different and because of this we would always recommend analysing  
315 HRV in patients with AF separately from those in SR. Nonetheless, our findings suggest that  
316 though HRV data may be less interpretable in AF, certain parameters do have discriminatory  
317 values rather than just the “random chaos” of ventricular response.

318

319 However, a feature of note is how few HRV changes were actually observed on HUT, even in  
320 the SR cohort. This highlights the importance of ageing on HRV as discussed above. In both

1  
2  
3 321 the oldest tertile in SR and the AF group, the non-linear measures were the only parameters  
4  
5 322 that changed significantly.  
6

7 323  
8

9  
10 324 One might ask why there is a differential effect depending on which measure of HRV is  
11  
12 325 employed. There is no gold standard technique for measuring HRV and currently no one  
13  
14 326 method can be described as superior to another; rather each provides complementary  
15  
16 327 information (Task Force of the European Society of Cardiology and the North American  
17  
18 328 Society of Pacing and Electrophysiology, 1996). Though many groups have attempted to  
19  
20 329 attribute individual HRV parameters to a particular limb of the autonomic nervous system, to  
21  
22 330 do so is an oversimplification of what is a complicated network. At best, HRV allows an  
23  
24 331 insight into autonomic modulation; as tone increases, modulation increases but once tone  
25  
26 332 remains elevated and saturation occurs, modulation decreases.  
27  
28

29 333  
30

### 31 334 *Non-linear measures of HRV*

32  
33  
34 335 There is little doubt that heart rate and its variability are complex phenomena which arise  
35  
36 336 from an intricate network of regulatory pathways. Heart rate is likely to be sensitive to initial  
37  
38 337 conditions but this dependence is likely to diverge exponentially with time. In mathematics  
39  
40 338 these types of systems are best described as non-linear, which are fundamentally different  
41  
42 339 from linear systems (examples of which include time and frequency domain analyses). This  
43  
44 340 description of the underlying principles of non-linear methods makes it immediately  
45  
46 341 appealing as a technique for AF due to the apparent randomness of the latter. We examined  
47  
48 342 three types of non-linear analysis: Poincaré plots (Hoshi, et al., 2013), DFA(Castiglioni et al.,  
49  
50 343 2011) and entropy (Porta et al., 2007).  
51

52 344  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 345 SD1 and SD2 represent the standard deviation in the minor and major axis of a fitted ellipse  
4  
5 346 to a plot of RR interval against the subsequent RR interval. However, as derivation of these  
6  
7 347 variables is based on simple statistics, groups have questioned whether analysis of Poincaré  
8  
9 348 plots truly reflects a non-linear technique. Hoshi and colleagues performed linear correlation  
10  
11 349 amongst time domain, frequency domain and non-linear HRV parameters in 65 healthy  
12  
13 350 individuals and 114 patients with coronary artery disease. Their data showed that SD1 is  
14  
15 351 highly correlated to RMSSD ( $r=0.99$ ) and SD2 to SDRR ( $r=0.95$ ) (Hoshi, et al., 2013).  
16  
17 352 Tulppo and colleagues showed a strong correlation between SD1 and HF ( $r=0.94$ ) as well as  
18  
19 353 SD2 and SDRR ( $r=0.99$ ) (Tulppo, Makikallio, Takala, Seppanen, & Huikuri, 1996). Our data  
20  
21 354 similarly reproduced these correlations (Table 5).  
22  
23  
24  
25  
26

27 356 DFA detects self-similarity. An  $\alpha$  value of 0.5 suggests that the signal is truly random  
28  
29 357 (white-noise) with larger values suggesting less noise (Brownian motion). When healthy  
30  
31 358 volunteers were sequentially challenged with atropine, propranolol and clonidine, it was  
32  
33 359 shown that DFA values rise with vagal blockade and decrease with sympathetic blockade  
34  
35 360 (Millar, Cotie, St Amand, McCartney, & Ditor, 2010).  
36  
37  
38  
39

40 362 Sample entropy measures regularity or randomness of heart rate variations. Higher values  
41  
42 363 indicate greater irregularity and are commonly a feature of health. During HUT, it is expected  
43  
44 364 that sample entropy decreases and this has been shown to be proportional to the angle of  
45  
46 365 HUT (Porta, et al., 2007).  
47  
48  
49

50 366

### 51 367 **Other data supporting the validity of using HRV in AF**

52 368 Measuring HRV in AF is not implausible; however, there remains a marked under  
53  
54 369 appreciation of it. The most basic search on PubMed reveals >18000 articles containing the  
55  
56  
57  
58  
59  
60



1  
2  
3 370 words 'heart rate variability' but only 402 articles using the combination of 'heart rate  
4  
5 371 variability' and 'atrial fibrillation'. A selection of the key publications are summarised below,  
6  
7 372 however, from a broader perspective, further work in this field is required especially using  
8  
9 373 the less validated non-linear techniques.  
10

11 374

12  
13  
14 375 Just as in SR there is a circadian rhythm of HR, a similar one is found in AF (Bollmann, et  
15  
16 376 al., 2006). Following on from this, the prognostic significance of HRV in large populations of  
17  
18 377 SR patients has been widely published and though there is a similar trend in patients with AF,  
19  
20 378 the literature is sparse (Frey et al., 1995; Platonov & Holmqvist, 2011). Yamada and  
21  
22 379 colleagues showed in 107 patients with AF and predominately a preserved left ventricular  
23  
24 380 ejection fraction, that HRV (non-linear markers only) could predict mortality (Yamada et al.,  
25  
26 381 2000). In the reduced ejection fraction population of MADIT-II, in a sub-group of patients  
27  
28 382 with AF (n= 68), those with a pNN20 <87 had a higher mortality (V. D. Corino et al., 2015).  
29  
30 383 Finally in a cohort of 155 patients with heart failure and AF who were enrolled into the  
31  
32 384 Muerte Subita en Insuficiencia Cardiaca (MUSIC) study, only non-linear HRV parameters  
33  
34 385 were found to be predictors of mortality, sudden cardiac death and heart failure  
35  
36 386 progression.(Cygankiewicz, et al., 2015)  
37  
38  
39  
40

41 387

42  
43 388 Our focus was on whether reactive changes in HRV could be identified in patient with AF  
44  
45 389 after a dynamic challenge. Van den Berg and colleagues compared the role of vagal activity  
46  
47 390 by using intravenous propranolol (SNS inhibitor) and methylatropine (PNS inhibitor) in 16  
48  
49 391 patients with chronic AF and 12 healthy men in SR (van den Berg et al., 1997). They  
50  
51 392 demonstrated that though there were significant differences at baseline between the two  
52  
53 393 groups in respect of HRV (SDRR, RMSDD, LF and HF), these parameters changed in  
54  
55 394 patients with AF in a similar direction albeit visually different magnitudes to healthy  
56  
57  
58  
59  
60

1  
2  
3 395 individuals when subjected to pharmacological sequential autonomic blockade. In a  
4  
5 396 subsequent blinded crossover trial in 60 patients with permanent AF, it was shown that both  
6  
7 397 beta-blockers and rate limiting calcium channel blockers lower heart rate and time domain  
8  
9 398 parameters (SDRR, RMSDD), whilst beta-blockers also increased irregularity (sample  
10  
11 399 entropy)(V. D. Corino, et al., 2015). Nagayoshi and colleagues documented RR interval and  
12  
13 400 SDRR in 23 patients (mean age 61 years) in response to tilt, Valsalva, hand grip and showed  
14  
15 401 that the response in patients with AF was similar to those of a historic SR population  
16  
17 402 (Nagayoshi, Janota, Hnatkova, Camm, & Malik, 1997).  
18  
19  
20  
21  
22

403

#### 404 **Limitations**

405 This is a retrospective study and is exposed to the inherent biases that are common with this  
406 design. We have tried to minimise selection bias by sampling consecutive patients. Observer  
407 bias was limited as the tilt-time around which the analysis was performed was based upon  
408 what was recorded at the time of the HUT. Ideally we would have wanted to study more  
409 patients with AF but we were surprised to find only 31 patients in total at two centres  
410 spanning in combination, 9 years of data in total. Our findings are applicable to patients with  
411 permanent AF who are above the age of 60 and likely to be on heart rate lowering or blood  
412 pressure lowering medications. Drugs, duration of AF (often difficult accurately to ascertain  
413 if the condition is asymptomatic) and other diagnoses (hypertension, heart failure, diabetes  
414 mellitus) are all known to induce autonomic remodelling and it is likely to account for the  
415 heterogeneity in response to HUT in our study. However, due to our limited sample size of  
416 patients with AF, we are unable confidently to perform further subgroup analyses to  
417 investigate the relative contributions of each of these explanatory variables on HRV.

418 **Comparisons of HRV and response to HUT between the population in AF and SR are**  
419 **confounded by the significantly increased use of cardiovascular medications and prevalence**

1  
2  
3 420 of hypertension in the AF group (Table 1). A larger and prospective study, with a broad  
4  
5 421 spectrum of AF patients matched by an equally broad spectrum of SR patients, might  
6  
7 422 overcome a number of these problems. Others have analysed blood pressure variability in  
8  
9 423 patients with AF and found less ‘white-noise’ artefact when compared to spectral analysis of  
10  
11 424 heart rate (V. D. A. Corino, Lombardi, & Mainardi, 2014). Future work may also study blood  
12  
13 425 pressure variability and baroreceptor function as markers of the ANS in patients with AF.  
14  
15  
16  
17

18  
19 427 We corrected for multiple statistical testing using a Bonferroni correction. However, an  
20  
21 428 accepted weakness is that it often results in a reduction in power, i.e. a conclusion that there  
22  
23 429 is no change, when one genuinely exists. To demonstrate the effects of this correction  
24  
25 430 explicitly, we have also provided those results that achieved significance at the conventional  
26  
27 431 critical p value of 0.05.  
28  
29  
30

### 31 432

### 32 433 **Conclusion**

33  
34 434 Our findings confirm the feasibility of using HRV in patients with AF. In particular, we were  
35  
36 435 able to detect changes in HRV in response to HUT using non-linear methods (DFA- $\alpha 2$  and  
37  
38 436 sample entropy) as compared to traditional linear methods in individuals with AF. However,  
39  
40 437 this finding invites a larger multicentre validation study. These findings may also prove to be  
41  
42 438 of value in assessing the effect of novel ANS-modulating treatments such as renal  
43  
44 439 denervation for diseases that predispose to AF, such as heart failure or hypertension.  
45  
46  
47

### 48 440

### 49 441 **Acknowledgements**

50  
51 442 HP, CH, ARL and CDM are supported by the NIHR Cardiovascular Biomedical Research  
52  
53 443 Unit. # HP and CH have contributed equally to this manuscript.  
54  
55  
56

57 444  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

445 **Conflict of interests**

446 None.

447

For Peer Review

448 **References:**

- 449 Ardell, J. L., Cardinal, R., Beaumont, E., Vermeulen, M., Smith, F. M., & Andrew Armour, J. (2014).  
450 Chronic spinal cord stimulation modifies intrinsic cardiac synaptic efficacy in the suppression  
451 of atrial fibrillation. *Auton Neurosci*, *186*, 38-44. doi: 10.1016/j.autneu.2014.09.017
- 452  
453 Bilchick, K. C., Fetics, B., Djoukeng, R., Fisher, S. G., Fletcher, R. D., Singh, S. N., . . . Berger, R. D.  
454 (2002). Prognostic value of heart rate variability in chronic congestive heart failure (Veterans  
455 Affairs' Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure). *Am J Cardiol*,  
456 *90*(1), 24-28.
- 457 Bollmann, A., Husser, D., Mainardi, L., Lombardi, F., Langley, P., Murray, A., . . . Sornmo, L. (2006).  
458 Analysis of surface electrocardiograms in atrial fibrillation: techniques, research, and clinical  
459 applications. *Europace*, *8*(11), 911-926. doi: 10.1093/europace/eul113
- 460  
461 Carrara, M., Carozzi, L., Moss, T. J., de Pasquale, M., Cerutti, S., Ferrario, M., . . . Moorman, J. R.  
462 (2015). Heart rate dynamics distinguish among atrial fibrillation, normal sinus rhythm and  
463 sinus rhythm with frequent ectopy. *Physiological Measurement*, *36*(9), 1873-1888. doi:  
464 10.1088/0967-3334/36/9/1873
- 465  
466 Castiglioni, P., Parati, G., Di Rienzo, M., Carabalona, R., Cividjian, A., & Quintin, L. (2011). Scale  
467 exponents of blood pressure and heart rate during autonomic blockade as assessed by  
468 detrended fluctuation analysis. *J Physiol*, *589*(Pt 2), 355-369. doi:  
469 10.1113/jphysiol.2010.196428
- 470  
471 Corino, V. D., Cygankiewicz, I., Mainardi, L. T., Stridh, M., Vasquez, R., Bayes de Luna, A., . . .  
472 Platonov, P. G. (2013). Association between atrial fibrillatory rate and heart rate variability in  
473 patients with atrial fibrillation and congestive heart failure. *Ann Noninvasive Electrocardiol*,  
474 *18*(1), 41-50. doi: 10.1111/anec.12019
- 475  
476 Corino, V. D., Ulimoen, S. R., Enger, S., Mainardi, L. T., Tveit, A., & Platonov, P. G. (2015). Rate-control  
477 drugs affect variability and irregularity measures of RR intervals in patients with permanent  
478 atrial fibrillation. *J Cardiovasc Electrophysiol*, *26*(2), 137-141. doi: 10.1111/jce.12580
- 479  
480 Corino, V. D. A., Lombardi, F., & Mainardi, L. T. (2014). Blood pressure variability in patients with  
481 atrial fibrillation. *Auton Neurosci*, *185*(0), 129-133. doi:  
482 <http://dx.doi.org/10.1016/j.autneu.2014.08.002>
- 483  
484 Cygankiewicz, I., Corino, V., Vazquez, R., Bayes-Genis, A., Mainardi, L., Zareba, W., . . . Platonov, P. G.  
485 (2015). Reduced Irregularity of Ventricular Response During Atrial Fibrillation and Long-term  
486 Outcome in Patients With Heart Failure. *Am J Cardiol*, *116*(7), 1071-1075. doi:  
487 10.1016/j.amjcard.2015.06.043
- 488  
489 Frey, B., Heinz, G., Binder, T., Wutte, M., Schneider, B., Schmidinger, H., . . . Pacher, R. (1995).  
490 Diurnal variation of ventricular response to atrial fibrillation in patients with advanced heart  
491 failure. *Am Heart J*, *129*(1), 58-65.

- 1  
2  
3 492 Hayano, J., Sakata, S., Okada, A., Mukai, S., & Fujinami, T. (1998). Circadian rhythms of  
4 493 atrioventricular conduction properties in chronic atrial fibrillation with and without heart  
5 494 failure. *J Am Coll Cardiol*, 31(1), 158-166.
- 6 495 Hayano, J., Yamasaki, F., Sakata, S., Okada, A., Mukai, S., & Fujinami, T. (1997). Spectral  
7 496 characteristics of ventricular response to atrial fibrillation. *Am J Physiol*, 273(6 Pt 2), H2811-  
8 497 2816.
- 9 498 Hillebrand, S., Gast, K. B., de Mutsert, R., Swenne, C. A., Jukema, J. W., Middeldorp, S., . . . Dekkers,  
10 499 O. M. (2013). Heart rate variability and first cardiovascular event in populations without  
11 500 known cardiovascular disease: meta-analysis and dose-response meta-regression. *Europace*,  
12 501 15(5), 742-749. doi: 10.1093/europace/eus341
- 13  
14 502  
15 503 Hoshi, R. A., Pastre, C. M., Vanderlei, L. C., & Godoy, M. F. (2013). Poincare plot indexes of heart rate  
16 504 variability: relationships with other nonlinear variables. *Auton Neurosci*, 177(2), 271-274.  
17 505 doi: 10.1016/j.autneu.2013.05.004
- 18  
19 506  
20 507 Laitinen, T., Niskanen, L., Geelen, G., Lansimies, E., & Hartikainen, J. (2004). Age dependency of  
21 508 cardiovascular autonomic responses to head-up tilt in healthy subjects. *J Appl Physiol*, 96(6),  
22 509 2333-2340. doi: 10.1152/jappphysiol.00444.2003
- 23  
24 510  
25 511 Leung, R. S., Bowman, M. E., Diep, T. M., Lorenzi-Filho, G., Floras, J. S., & Bradley, T. D. (2005).  
26 512 Influence of Cheyne-Stokes respiration on ventricular response to atrial fibrillation in heart  
27 513 failure. *J Appl Physiol*, 99(5), 1689-1696. doi: 10.1152/jappphysiol.00027.2005
- 28  
29 514  
30 515 Lim, P. B., Malcolm-Lawes, L. C., Stuber, T., Koa-Wing, M., Wright, I. J., Tillin, T., . . . Kanagaratnam,  
31 516 P. (2011). Feasibility of multiple short, 40-s, intra-procedural ECG recordings to detect  
32 517 immediate changes in heart rate variability during catheter ablation for arrhythmias. *Journal*  
33 518 *of Interventional Cardiac Electrophysiology*, 32(2), 163-171. doi: 10.1007/s10840-011-9580-2
- 34  
35 519  
36 520 Mehlsen, J., Kaijser, M. N., & Mehlsen, A. B. (2008). Autonomic and electrocardiographic changes in  
37 521 cardioinhibitory syncope. *Europace*, 10(1), 91-95. doi: 10.1093/europace/eum237
- 38  
39 522  
40 523 Millar, P. J., Cotie, L. M., St Amand, T., McCartney, N., & Ditor, D. S. (2010). Effects of autonomic  
41 524 blockade on nonlinear heart rate dynamics. *Clin Auton Res*, 20(4), 241-247. doi:  
42 525 10.1007/s10286-010-0058-6
- 43  
44 526  
45 527 Mouro, L., Bouhaddi, M., Gandelin, E., Cappelle, S., Nguyen, N. U., Wolf, J.-P., . . . Regnard, J. (2007).  
46 528 Conditions of autonomic reciprocal interplay versus autonomic co-activation: Effects on non-  
47 529 linear heart rate dynamics. *Auton Neurosci*, 137(1-2), 27-36. doi:  
48 530 <http://dx.doi.org/10.1016/j.autneu.2007.06.284>
- 49  
50 531  
51 532 Nagayoshi, H., Janota, T., Hnatkova, K., Camm, A. J., & Malik, M. (1997). Autonomic modulation of  
52 533 ventricular rate in atrial fibrillation. *Am J Physiol*, 272(4 Pt 2), H1643-1649.
- 53  
54 534 Patel, H. C., Rosen, S. D., Lindsay, A., Hayward, C., Lyon, A. R., & di Mario, C. (2013). Targeting the  
55 535 autonomic nervous system: Measuring autonomic function and novel devices for heart  
56 536 failure management. *Int J Cardiol*, 170(2), 107-117. doi: 10.1016/j.ijcard.2013.10.058

- 1  
2  
3 537  
4 538 Petersen, M. E., Williams, T. R., Gordon, C., Chamberlain-Webber, R., & Sutton, R. (2000). The normal  
5 539 response to prolonged passive head up tilt testing. *Heart*, *84*(5), 509-514.  
6 540 Platonov, P. G., & Holmqvist, F. (2011). Atrial fibrillatory rate and irregularity of ventricular response  
7 541 as predictors of clinical outcome in patients with atrial fibrillation. *J Electrocardiol*, *44*(6),  
8 542 673-677. doi: 10.1016/j.jelectrocard.2011.07.024  
9  
10 543  
11 544 Porta, A., Gneccchi-Ruscione, T., Tobaldini, E., Guzzetti, S., Furlan, R., & Montano, N. (2007).  
12 545 Progressive decrease of heart period variability entropy-based complexity during graded  
13 546 head-up tilt. *J Appl Physiol*, *103*(4), 1143-1149. doi: 10.1152/jappphysiol.00293.2007  
14  
15 547  
16 548 Rawles, J. M., & Rowland, E. (1986). Is the pulse in atrial fibrillation irregularly irregular? *Br Heart J*,  
17 549 *56*(1), 4-11.  
18 550 Shiogai, Y., Stefanovska, A., & McClintock, P. V. E. (2010). Nonlinear dynamics of cardiovascular  
19 551 ageing. *Physics Reports*, *488*(2-3), 51-110. doi: 10.1016/j.physrep.2009.12.003  
20  
21 552  
22 553 Sosnowski, M., Macfarlane, P. W., & Tendera, M. (2011). Determinants of a reduced heart rate  
23 554 variability in chronic atrial fibrillation. *Ann Noninvasive Electrocardiol*, *16*(4), 321-326. doi:  
24 555 10.1111/j.1542-474X.2011.00458.x  
25  
26 556  
27 557 Tarvainen, M. P., Niskanen, J. P., Lipponen, J. A., Ranta-Aho, P. O., & Karjalainen, P. A. (2014). Kubios  
28 558 HRV--heart rate variability analysis software. *Comput Methods Programs Biomed*, *113*(1),  
29 559 210-220. doi: 10.1016/j.cmpb.2013.07.024  
30  
31 560  
32 561 Task Force of the European Society of Cardiology and the North American Society of Pacing and  
33 562 Electrophysiology. (1996). Heart rate variability. Standards of measurement, physiological  
34 563 interpretation, and clinical use. Task Force of the European Society of Cardiology and the  
35 564 North American Society of Pacing and Electrophysiology. *Eur Heart J*, *17*(3), 354-381.  
36 565 Tulppo, M. P., Makikallio, T. H., Takala, T. E., Seppanen, T., & Huikuri, H. V. (1996). Quantitative beat-  
37 566 to-beat analysis of heart rate dynamics during exercise. *Am J Physiol*, *271*(1 Pt 2), H244-252.  
38 567  
39 568 van den Berg, M. P., Haaksma, J., Brouwer, J., Tieleman, R. G., Mulder, G., & Crijns, H. J. (1997). Heart  
40 569 rate variability in patients with atrial fibrillation is related to vagal tone. *Circulation*, *96*(4),  
41 570 1209-1216.  
42 571 Voss, A., Schroeder, R., Heitmann, A., Peters, A., & Perz, S. (2015). Short-Term Heart Rate  
43 572 Variability—Influence of Gender and Age in Healthy Subjects. *PLoS One*, *10*(3), e0118308.  
44 573 doi: 10.1371/journal.pone.0118308  
45  
46 574  
47 575 Yamada, A., Hayano, J., Sakata, S., Okada, A., Mukai, S., Ohte, N., & Kimura, G. (2000). Reduced  
48 576 ventricular response irregularity is associated with increased mortality in patients with  
49 577 chronic atrial fibrillation. *Circulation*, *102*(3), 300-306.  
50  
51 578  
52  
53 579  
54  
55  
56  
57  
58  
59  
60

	<b>Atrial Fibrillation (n=31)</b>	<b>Sinus Rhythm (n=69)</b>	<b>p</b>
<b>Age</b>	74.3 (68.9, 83.8)	70.3 (62.9, 77.7)	0.056
<b>Male</b>	20 (64.5%)	46 (66.7%)	1.000
<b>Diabetes</b>	5 (16.1%)	5 (7.2%)	0.277
<b>Hypertension</b>	23 (74.2%)	11 (15.9%)	<0.001
<b>Heart Failure</b>	2 (6.5%)	0 (0%)	0.094
<b>Medications</b>			
ACEi/ARB	15 (48.4%)	12 (17.4%)	0.002
Beta-blockers	10 (32.3%)	3 (4.3%)	<0.001
CCB	8 (25.8%)	3 (4.3%)	0.003
Digoxin	7 (22.6%)	0 (0%)	<0.001
Diuretics	7 (22.6%)	6 (8.7%)	0.103
Median	2 (1, 2)	0 (0, 0)	<0.001

**Table 1: Demographics, past medical and medication history of the patients with atrial fibrillation and age matched sinus rhythm. Data are presented as median (quartile 1, quartile 3) or count (%). ACEi- angiotensin converting enzyme inhibitor; ARB- angiotensin receptor blocker; CCB- calcium channel blocker**



		Baseline			Change from baseline after HUT		
	Cohort	AF (n=31)	SR (n=81)	P (AF vs SR)	AF	SR	P (AF vs SR)
Haemodynamics	SBP (mmHg)	126.5 (112.0, 139.1)	123.1 (112.7, 134.9)	0.469	+5.2 (-2.5, 12.1)	+6.6 (-1.7, 16.6)**	0.431
	DBP (mmHg)	79.2 (68.9, 83.5)	77.8 (70.6, 84.5)	0.871	+4.8 (-0.6, 13.1)*	+10.4 (1.5, 16.1)**	0.100
	HR (beats/min)	74.9 (67.6, 87.5)	70.7 (60.9, 78.2)	0.018	+3.8 (1.4, 7.1)**	+4.6 (1.7, 8.2)**	0.776
	Stroke index (ml/m <sup>2</sup> )	36.8 (25.9, 42.2)	34.7 (29.9, 41.5)	0.729	-5.2 (-8.1, 1.0)*	-5.7 (-10.0, -1.1)**	0.417
	Cardiac index (L/[min.m <sup>2</sup> ])	2.41 (2.12, 2.94)	2.52 (2.17, 2.98)	0.663	-0.13 (-0.44, 0.26)	-0.26 (-0.54, 0.06)**	0.326
	TPR index (dyne*s*m <sup>2</sup> /cm <sup>5</sup> )	3464 (2666, 3792)	2930 (2585, 3488)	0.252	+612 (-168, 1092)*	+628 (106, 1028)**	0.515
Time	SDNN (ms)	102.8 (28.3, 160.4)	39.2 (25.3, 57.1)	0.003	+0.9 (-13.9, 18.4)	+3.4 (-6.7, 18.8)*	0.396
	RMSSD (ms)	139.2 (18.4, 208.1)	26.9 (15.9, 47.2)	0.001	-5.5 (-21.4, 4.2)	-2.2 (-22.1, 21.5)	0.291

Frequency	LF (ms <sup>2</sup> )	2075 (135, 5243)	254 (156, 612)	0.005	65.1 (-223, 320)	-21.6 (-151, 137)	0.364
	HF (ms <sup>2</sup> )	3921 (106, 10491)	209 (75, 539)	0.001	-92.5 (-2124, 119)*	-28.0 (-234, 36)*	0.149
	LF/HF	0.58 (0.46, 1.02)	1.39 (0.80, 2.25)	<0.001	+0.10 (-0.12, 0.35)*	+0.61 (-0.32, 2.33)**	0.216
	LFnu (%)	36.4 (31.4, 50.4)	58.0 (44.3, 69.2)	<0.001	+4.4 (-4.0, 9.9)	+7.1 (-4.3, 17.5)**	0.341
	HFnu (%)	63.1 (49.6, 68.2)	41.8 (30.7, 55.6)	<0.001	-4.2 (-9.8, 3.8)	-7.1 (-17.2, 4.3)**	0.331
Non linear	SD1 (ms)	98.5 (13.0, 147.4)	19.0 (11.3, 33.4)	0.001	-3.9 (-15.2, 3.0)	-1.4 (-10.9, 5.8)	0.393
	SD2 (ms)	110.6 (34.9, 163.9)	49.3 (33.6, 66.4)	0.006	+1.9 (-14.4, 29.3)	+4.7 (-6.4, 26.7)**	0.669
	DFA- $\alpha$ 1	0.70 (0.61, 1.01)	1.06 (0.84, 1.22)	<0.001	+0.01 (-0.11, 0.09)	+0.07 (-0.14, 0.45)*	0.179
	DFA- $\alpha$ 2	0.69 (0.54, 0.86)	0.94 (0.80, 1.11)	<0.001	+0.14 (-0.03, 0.32)**	+0.14 (-0.03, 0.36)**	0.806
	Sample Entropy	1.78 (1.26, 2.05)	1.26 (0.94, 1.55)	<0.001	-0.17 (-0.50, -0.01)**	-0.25 (-0.55, 0.04)**	0.887

Table 2: Baseline and change with HUT of haemodynamic and HRV data. \*=  $p \leq 0.05$  (within group delta from baseline, paired t-test)  
 \*\*= $p \leq 0.005$  (within group delta from baseline, paired t-test). DFA1, DFA2 and Sample Entropy are dimensionless.

1  
2  
3  
4  
5 **SBP- systolic blood pressure; DBP- diastolic blood pressure; HR- heart rate; TPR- total peripheral resistance; SDNN- standard**  
6 **deviation of the RR interval; RMSSD- root of the mean squared differences of successive RR intervals; LFnu- low frequency power in**  
7 **normalized units; HFnu- high frequency power in normalized units; SD1- minor axis on Poincaré plots; SD2- major axis on Poincaré**  
8 **plots, DFA- detrended fluctuation analysis**  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

For Peer Review

<b>Tertiles of age</b>	<b>0-30 (n=50)</b>	<b>30-60 (n=69)</b>	<b>60+ (n=57)</b>	<b>p</b>
<b>Age</b>	22.0 (18.5, 24.9)	47.1 (38.4, 52.4)	72.7 (66.2, 79.4)	<0.001
<b>Male</b>	20 (40.0%)	34 (49.3%)	38 (66.7%)	0.018
<b>Diabetes</b>	9 (18.0%)	5 (7.2%)	4 (7.0%)	0.131
<b>Hypertension</b>	10 (20.0%)	14 (20.3%)	9 (15.8%)	0.807
<b>Heart Failure</b>	1 (2.0%)	0 (0%)	0 (0%)	0.284
<b>Medications</b>				
ACEi/ARB	6 (12.0%)	10 (14.5%)	10 (17.5%)	0.659
Beta-blockers	4 (8.0%)	6 (8.7%)	2 (3.5%)	0.522
CCB	5 (10.0%)	6 (8.7%)	3 (5.3%)	0.648
Diuretics	4 (8.0%)	3 (4.3%)	5 (8.8%)	0.562
Total	0.0 (0.0, 0.3)	0.0 (0.0, 0.0)	0.0 (0.0, 0.0)	0.947

**Table 3: Demographics, past medical and medication history of the patients in sinus rhythm across tertiles of age. Data are presented as median (quartile 1, quartile 3) or count (%). Abbreviations as per Table 1**

Peer Review

		Baseline				Change from baseline after HUT			
	Age Tertiles (years)	0-30 (n=50)	30-60 (n=69)	60+ (n=57)	P (between groups)	0-30	30-60	60+	P (between groups)
Haemodynamics	SBP (mmHg)	114.5 (108.4, 122.6)	124.9 (112.8, 135.1)	123.3 (113.2, 135.0)	0.004	+9.3 (3.7, 11.0)**	+6.6 (0.3, 17.0)**	+6.7 (-1.4, 14.7)**	0.419
	DBP (mmHg)	73.8 (67.7, 81.5)	83.6 (76.5, 88.6)	75.9 (69.8, 81.6)	<0.001	+14.3 (6.2, 19.3)**	+10.6 (2.2, 10.6)**	+10.3 (2.5, 15.7)**	0.102
	HR (beats/min)	72.5 (64.8, 79.7)	72.2 (61.9, 80.6)	71.4 (61.9, 78.5)	0.800	+8.8 (5.6, 14.9)**	+6.1 (2.8, 11.2)**	+4.4 (1.1, 7.3)**	<0.001
	Stroke index (ml/m <sup>2</sup> )	50.2 (42.1, 57.3)	38.2 (31.3, 44.6)	34.8 (29.2, 40.5)	<0.001	-9.8 (-15.6, -4.5)**	-7.8 (-13.0, -1.7)**	-5.1 (-9.0, -1.5)**	0.004
	Cardiac index (L/[min.m <sup>2</sup> ])	3.39 (3.06, 4.08)	2.68 (2.16, 3.15)	2.52 (2.20, 3.05)	<0.001	-0.35 (-0.78, 0.06)**	-0.33 (-0.65, 0.02)**	-0.25 (-0.59, 0.09)**	0.582
	TPR index (dyne*s*m <sup>2</sup> /cm <sup>5</sup> )	1985 (1714, 2479)	2960 (2450, 3675)	2925 (2516, 3305)	<0.001	+532 (162, 750)**	+661 (328, 1224)**	+617 (7.7, 1030)**	0.218
Time-domain	SDRR (ms)	70.2 (48.9, 88.5)	43.7 (29.6, 62.4)	40.2 (26.3, 58.3)	<0.001	+0.2 (-9.5, 8.6)**	+7.0 (-7.0, 19.6)*	+1.8 (-7.8, 18.7)	0.144
	RMSSD (ms)	47.8 (37.0, 82.2)	30.2 (17.4, 55.2)	27.9 (16.7, 52.7)	<0.001	-19.3 (-49.9, -4.2)**	-4.0 (-18.5, 14.5)	+0.6 (-26.8, 19.0)	0.001
Frequency-domain	LF (ms <sup>2</sup> )	1092 (651, 2381)	492 (235, 806)	251 (142, 600)	<0.001	-14.8 (-350, -15)**	+24.2 (-150, 430)	-52.6 (-155, 126)	0.357

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

	<b>HF (ms<sup>2</sup>)</b>	1085 (456, 2485)	310 (108, 926)	189 (76, 584)	<0.001	-592 (-1651, -592) **	-71.9 (-392, 21) **	-23.6 (-227, 62)	<0.001
	<b>LF/HF</b>	1.13 (0.68, 1.85)	1.69 (0.93, 2.37)	1.25 (0.68, 2.13)	0.037	+1.56 (0.82, 3.15) **	+1.23 (0.40, 3.57) **	+0.33 (-0.25, 2.33) **	0.005
	<b>LFnu (%)</b>	53.0 (40.3, 64.8)	62.7 (48.0, 70.3)	55.6 (40.4, 67.9)	0.037	+20.3 (12.5, 26.3) **	+12.2 (3.6, 23.5) **	+6.3 (-4.8, 19.4) *	<0.001
	<b>HFnu (%)</b>	46.9 (35.1, 59.6)	37.2 (29.6, 51.8)	44.4 (32.0, 59.1)	0.037	-20.2 (-26.2, -12.3) **	-12.1 (-23.4, -3.58) **	-6.3 (-19.1, 4.8) *	<0.001
<b>Non linear</b>									
	<b>SD1 (ms)</b>	33.9 (26.2, 58.2)	21.4 (12.3, 39.1)	19.8 (11.8, 37.3)	<0.001	-14.5 (-24.7, -2.8) **	-3.3 (-14.0, 1.9) **	-1.4 (-10.4, 7.9)	<0.001
	<b>SD2 (ms)</b>	84.9 (62.7, 108.8)	55.7 (38.8, 81.3)	49.3 (34.1, 66.4)	<0.001	+5.2 (-8.5, 14.3)	+9.4 (-6.2, 28.4) **	+3.5 (-7.3, 27.2)	0.406
	<b>DFA-α1</b>	1.00 (0.84, 1.26)	1.13 (0.92, 1.33)	1.04 (0.77, 1.19)	0.082	+0.28 (0.11, 0.48) **	+0.24 (-0.06, 0.42) **	+0.06 (-0.21, 0.49)	0.010
	<b>DFA-α2</b>	0.84 (0.78, 0.94)	0.87 (0.77, 1.05)	0.94 (0.80, 1.06)	0.142	+0.13 (-0.04, 0.28) **	+0.12 (-0.03, 0.25) **	+0.18 (-0.3, 0.37) **	0.260
	<b>Sample Entropy</b>	1.58 (1.36, 1.77)	1.42 (1.19, 1.63)	1.20 (0.86, 1.49)	<0.001	-0.45 (-0.66, -0.18) **	-0.30 (-0.60, -0.05) **	-0.20 (-0.55, 0.13) **	0.070

**Table 4: Baseline and change with HUT of haemodynamic and HRV data across the tertiles of age in patients with sinus rhythm. Data are presented as median (quartile 1, quartile 3). \* = p≤0.05 (within group delta from baseline) \*\* = p≤0.005 (within group delta from baseline). Abbreviations as per Table 2.**

AF SR	SDNN (ms)	RMSSD (ms)	LF (ms <sup>2</sup> )	HF (ms <sup>2</sup> )	LF/HF	LFnu (%)	HFnu (%)	SD1 (ms)	SD2 (ms)	DFA- $\alpha$ 1	DFA- $\alpha$ 2	Sample Entropy
SDNN (ms)		0.992 P<0.001	0.926 P<0.001	0.943 P<0.001	-0.476 P=0.007	-0.614 P<0.001	0.613 P<0.001	0.992 P<0.001	0.996 P<0.001	-0.572 P=0.001	-0.737 P<0.001	0.703 P<0.001
RMSSD (ms)	0.892 P<0.001		0.908 P<0.001	0.935 P<0.001	-0.514 P=0.003	-0.664 P<0.001	0.663 P<0.001	1.000 P<0.001	0.976 P<0.001	-0.637 P<0.001	-0.762 P<0.001	0.735 P<0.001
LF (ms <sup>2</sup> )	0.871 P<0.001	0.740 P<0.001		0.970 P<0.001	-0.366 P=0.043	-0.474 P=0.007	0.474 P=0.007	0.908 P<0.001	0.930 P<0.001	-0.461 P=0.009	-0.676 P<0.001	0.663 P<0.001
HF (ms <sup>2</sup> )	0.841 P<0.001	0.878 P<0.001	0.765 P<0.001		-0.399 P=0.26	-0.530 P=0.002	0.529 P=0.002	0.935 P<0.001	0.939 P<0.001	-0.506 P=0.004	-0.659 P<0.001	0.696 P<0.001
LF/HF	-0.227 P=0.002	-0.444 P<0.001	-0.106 P=0.160	-0.327 P<0.001		0.904 P<0.001	-0.905 P<0.001	-0.514 P=0.003	-0.453 P=0.010	0.886 P<0.001	0.393 P=0.029	-0.448 P=0.012
LFnu (%)	-0.274 P<0.001	-0.553 P<0.001	-0.063 P=0.403	-0.444 P<0.001	0.823 P<0.001		-1.000 P<0.001	-0.664 P<0.001	-0.580 P=0.001	0.956 P<0.001	0.595 P<0.001	-0.555 P=0.001
HFnu (%)	0.275 P<0.001	0.553 P<0.001	0.065 P=0.389	0.446 P<0.001	-0.823 P<0.001	-1.000 P<0.001		0.663 P<0.001	0.579 P=0.001	-0.955 P<0.001	-0.595 P<0.001	0.555 P=0.001
SD1 (ms)	0.892 P<0.001	1.000 P<0.001	0.740 P<0.001	0.879 P<0.001	-0.444 P<0.001	-0.553 P<0.001	0.553 P<0.001		0.976 P<0.001	-0.637 P<0.001	-0.762 P<0.001	0.735 P<0.001
SD2 (ms)	0.986 P<0.001	0.807 P<0.001	0.880 P<0.001	0.785 P<0.001	-0.150 P=0.047	-0.163 P=0.031	0.164 P=0.029	0.807 P<0.001		-0.538 P=0.002	-0.713 P<0.001	0.678 P<0.001
DFA- $\alpha$ 1	-0.242 P=0.001	-0.539 P<0.001	-0.066 P=0.381	-0.375 P<0.001	0.731 P<0.001	0.907 P<0.001	-0.904 P<0.001	-0.539 P<0.001	-0.123 P=0.103		0.551 P=0.001	-0.598 P<0.001
DFA- $\alpha$ 2	-0.081 P=0.287	-0.227 P=0.002	-0.189 P=0.012	-0.100 P=0.188	0.187 P=0.013	0.156 P=0.039	-0.154 P=0.041	-0.227 P=0.002	-0.032 P=0.674	0.231 P=0.002		-0.698 P<0.001
Sample Entropy	-0.024 P=0.754	0.111 P=0.141	0.096 P=0.204	0.175 P=0.020	-0.279 P<0.001	-0.162 P=0.032	0.164 P=0.029	-0.111 P=0.141	-0.057 P=0.453	-0.178 P=0.018	-0.189 P=0.012	

Table 5: Correlations (r) between heart rate variability parameters in the sinus rhythm (SR- in white) population (N=176) and atrial fibrillation (AF- in grey) population (N=31). Abbreviations as per Table 2.